NASDAQ:ARRY - Array Biopharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$15.75 0.00 (0.00 %)
(As of 05/20/2018 07:29 AM ET)
Previous Close$15.75
Today's Range$15.64 - $16.09
52-Week Range$7.15 - $18.78
Volume1.94 million shs
Average Volume2.46 million shs
Market Capitalization$3.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.73

About Array Biopharma (NASDAQ:ARRY)

Array Biopharma logoArray BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Receive ARRY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ARRY
CUSIP04269X10
Phone303-381-6600

Debt

Debt-to-Equity Ratio0.36
Current Ratio5.73
Quick Ratio5.73

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$150.85 million
Price / Sales21.99
Cash FlowN/A
Price / CashN/A
Book Value$1.26 per share
Price / Book12.50

Profitability

EPS (Most Recent Fiscal Year)($0.72)
Net Income$-116,810,000.00
Net Margins-72.33%
Return on Equity-96.65%
Return on Assets-31.97%

Miscellaneous

Employees209
Outstanding Shares210,640,000

Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions

What is Array Biopharma's stock symbol?

Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array Biopharma's earnings last quarter?

Array Biopharma Inc (NASDAQ:ARRY) issued its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.11. The biopharmaceutical company had revenue of $66.37 million for the quarter, compared to analyst estimates of $28.81 million. Array Biopharma had a negative net margin of 72.33% and a negative return on equity of 96.65%. The business's revenue was up 99.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.21) EPS. View Array Biopharma's Earnings History.

When is Array Biopharma's next earnings date?

Array Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Array Biopharma.

What price target have analysts set for ARRY?

8 equities research analysts have issued 1 year target prices for Array Biopharma's stock. Their forecasts range from $13.00 to $24.00. On average, they anticipate Array Biopharma's stock price to reach $18.3750 in the next year. View Analyst Ratings for Array Biopharma.

What are Wall Street analysts saying about Array Biopharma stock?

Here are some recent quotes from research analysts about Array Biopharma stock:
  • 1. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (5/14/2018)
  • 2. Cantor Fitzgerald analysts commented, "ARRY and ASLAN (NC) have updated a 2011 agreement for varlitinib, a pan-HER2 inhibitor, providing nearer term cash to ARRY in exchange for commercialization rights (the prior agreement covered development)." (1/3/2018)

Who are some of Array Biopharma's key competitors?

Who are Array Biopharma's key executives?

Array Biopharma's management team includes the folowing people:
  • Mr. Ron Squarer, Chief Exec. Officer and Director (Age 51)
  • Mr. Jason Haddock, Chief Financial Officer (Age 48)
  • Mr. Andrew R. Robbins, Chief Operating Officer (Age 42)
  • Dr. Victor Sandor M.D., C.M, Chief Medical Officer (Age 52)
  • Dr. Nicholas A. Saccomano Ph.D., Chief Scientific Officer (Age 59)

Has Array Biopharma been receiving favorable news coverage?

Media stories about ARRY stock have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Array Biopharma earned a news sentiment score of 0.08 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.65 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Array Biopharma's major shareholders?

Array Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.68%), Franklin Resources Inc. (3.96%), BVF Inc. IL (2.44%), Farallon Capital Management LLC (1.47%), Pinnacle Associates Ltd. (1.25%) and Northern Trust Corp (1.17%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Redmile Group, Llc, Ron Squarer and Victor Sandor. View Institutional Ownership Trends for Array Biopharma.

Which institutional investors are selling Array Biopharma stock?

ARRY stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BVF Inc. IL, venBio Select Advisor LLC, Franklin Resources Inc., Eversept Partners LLC, Pinnacle Associates Ltd., Trexquant Investment LP and Russell Investments Group Ltd.. Company insiders that have sold Array Biopharma company stock in the last year include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Ron Squarer and Victor Sandor. View Insider Buying and Selling for Array Biopharma.

Which institutional investors are buying Array Biopharma stock?

ARRY stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, American Century Companies Inc., Columbus Circle Investors, Neuberger Berman Group LLC, BlackRock Inc., PointState Capital LP, A.R.T. Advisors LLC and UBS Group AG. View Insider Buying and Selling for Array Biopharma.

How do I buy shares of Array Biopharma?

Shares of ARRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Array Biopharma's stock price today?

One share of ARRY stock can currently be purchased for approximately $15.75.

How big of a company is Array Biopharma?

Array Biopharma has a market capitalization of $3.32 billion and generates $150.85 million in revenue each year. The biopharmaceutical company earns $-116,810,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Array Biopharma employs 209 workers across the globe.

How can I contact Array Biopharma?

Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]


MarketBeat Community Rating for Array Biopharma (ARRY)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  344 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  530
MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Array Biopharma (NASDAQ:ARRY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Array Biopharma in the last 12 months. Their average twelve-month price target is $18.3750, suggesting that the stock has a possible upside of 16.67%. The high price target for ARRY is $24.00 and the low price target for ARRY is $13.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.88
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.3750$17.25$17.25$14.1250
Price Target Upside: 16.67% upside1.71% downside1.71% downside35.17% upside

Array Biopharma (NASDAQ:ARRY) Consensus Price Target History

Price Target History for Array Biopharma (NASDAQ:ARRY)

Array Biopharma (NASDAQ:ARRY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018Cantor FitzgeraldSet Price TargetBuy$24.00HighView Rating Details
2/7/2018Leerink SwannBoost Price TargetOutperform ➝ Outperform$19.00 ➝ $20.00LowView Rating Details
2/7/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$20.00 ➝ $23.00HighView Rating Details
2/6/2018SunTrust BanksReiterated RatingBuy$20.00LowView Rating Details
12/22/2017Jefferies GroupBoost Price TargetBuy$13.00N/AView Rating Details
9/20/2017Piper JaffrayReiterated RatingOverweight$14.00 ➝ $18.00LowView Rating Details
9/11/2017CowenReiterated RatingOutperform$14.00 ➝ $15.00HighView Rating Details
9/11/2017JPMorgan ChaseReiterated RatingBuy$14.00HighView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Array Biopharma (NASDAQ:ARRY) Earnings History and Estimates Chart

Earnings by Quarter for Array Biopharma (NASDAQ:ARRY)

Array Biopharma (NASDAQ:ARRY) Earnings Estimates

2018 EPS Consensus Estimate: ($0.99)
2019 EPS Consensus Estimate: ($0.95)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.31)($0.19)($0.25)
Q2 20182($0.32)($0.18)($0.25)
Q3 20183($0.27)($0.18)($0.21)
Q4 20184($0.35)($0.24)($0.28)
Q1 20192($0.29)($0.24)($0.27)
Q2 20192($0.29)($0.01)($0.15)
Q3 20192($0.29)($0.23)($0.26)
Q4 20192($0.31)($0.23)($0.27)

Array Biopharma (NASDAQ ARRY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.26)N/AView Earnings Details
5/9/2018Q3 2018($0.22)($0.11)$28.81 million$66.37 millionViewN/AView Earnings Details
2/6/2018Q2 2018($0.23)($0.17)$26.81 million$42.21 millionViewN/AView Earnings Details
10/31/2017Q1 2018($0.22)($0.22)$33.74 million$29.75 millionViewN/AView Earnings Details
8/9/2017Q4 2017($0.21)($0.17)$28.64 million$33.80 millionViewListenView Earnings Details
5/10/2017Q3 2017($0.1610)($0.21)$38.28 million$33.28 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.18)($0.14)$31.90 million$44.50 millionViewListenView Earnings Details
11/1/2016Q117($0.16)($0.20)$32.47 million$39.30 millionViewListenView Earnings Details
8/4/2016Q416($0.14)($0.17)$41.51 million$43.20 millionViewListenView Earnings Details
5/3/2016Q316($0.12)($0.16)$30.35 million$43.00 millionViewListenView Earnings Details
2/2/2016Q216($0.06)($0.17)$32.70 million$35.40 millionViewListenView Earnings Details
11/4/2015Q116($0.18)($0.15)$14.02 million$16.20 millionViewListenView Earnings Details
8/3/2015Q415($0.16)($0.09)$10.29 million$12.30 millionViewListenView Earnings Details
5/4/2015Q315($0.01)$0.37$6.00 million$6.60 millionViewListenView Earnings Details
2/3/2015Q215($0.20)($0.06)$10.20 million$26.92 millionViewListenView Earnings Details
11/4/2014Q115($0.22)($0.21)$6.35 million$6.07 millionViewListenView Earnings Details
8/12/2014Q414($0.23)($0.22)$8.10 million$6.00 millionViewListenView Earnings Details
4/29/2014Q314($0.21)($0.20)$9.40 million$7.80 millionViewListenView Earnings Details
2/4/2014Q214($0.16)($0.13)$13.49 million$14.10 millionViewListenView Earnings Details
10/31/2013Q114($0.18)($0.13)$11.20 million$14.20 millionViewListenView Earnings Details
8/7/2013Q4 2013($0.13)($0.06)$16.13 million$25.40 millionViewListenView Earnings Details
5/6/2013Q3 2013($0.14)($0.19)$14.54 million$10.00 millionViewListenView Earnings Details
2/4/2013Q2 2013($0.14)($0.10)$16.52 million$18.40 millionViewListenView Earnings Details
10/29/2012Q113($0.15)($0.13)$16.70 million$15.80 millionViewN/AView Earnings Details
8/13/2012($0.11)($0.09)ViewN/AView Earnings Details
4/30/2012($0.16)($0.11)ViewN/AView Earnings Details
1/30/2012($0.12)($0.06)ViewN/AView Earnings Details
10/31/2011Q1 2012($0.19)($0.06)ViewN/AView Earnings Details
8/8/2011Q4 2011($0.27)($0.17)ViewN/AView Earnings Details
5/2/2011($0.25)($0.20)ViewN/AView Earnings Details
1/31/2011($0.28)($0.23)ViewN/AView Earnings Details
11/8/2010Q1 2011($0.28)($0.20)ViewN/AView Earnings Details
8/9/2010Q4 2010($0.32)($0.30)ViewN/AView Earnings Details
5/3/2010Q3 2010($0.34)($0.30)ViewN/AView Earnings Details
2/1/2010Q2 2010($0.55)($0.44)ViewN/AView Earnings Details
11/2/2009Q1 2010($0.55)($0.52)ViewN/AView Earnings Details
8/10/2009Q4 2009($0.55)($0.55)ViewN/AView Earnings Details
5/4/2009Q3 2009($0.58)($0.55)ViewN/AView Earnings Details
2/2/2009Q2 2009($0.65)($0.57)ViewN/AView Earnings Details
11/3/2008Q1 2009($0.65)($0.63)ViewN/AView Earnings Details
8/11/2008Q4 2008($0.63)($0.68)ViewN/AView Earnings Details
5/5/2008Q3 2008($0.51)($0.51)ViewN/AView Earnings Details
2/4/2008Q2 2008($0.46)($0.43)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Array Biopharma (NASDAQ:ARRY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Array Biopharma (NASDAQ ARRY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.18%
Institutional Ownership Percentage: 96.92%
Insider Trading History for Array Biopharma (NASDAQ:ARRY)
Institutional Ownership by Quarter for Array Biopharma (NASDAQ:ARRY)

Array Biopharma (NASDAQ ARRY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2018Lunsen Gil J VanDirectorSell21,500$15.36$330,240.0031,797View SEC Filing  
4/18/2018Lunsen Gil J VanDirectorSell21,500$15.19$326,585.0024,797View SEC Filing  
4/3/2018Victor SandorInsiderSell8,689$15.35$133,376.15View SEC Filing  
3/21/2018Lunsen Gil J VanDirectorSell21,500$16.76$360,340.0026,297View SEC Filing  
3/9/2018Victor SandorInsiderSell156,016$17.71$2,763,043.36View SEC Filing  
2/21/2018Lunsen Gil J VanDirectorSell21,500$17.16$368,940.0032,797View SEC Filing  
2/9/2018Charles M BaumDirectorSell50,000$16.90$845,000.0035,000View SEC Filing  
1/17/2018Lunsen Gil J VanDirectorSell21,500$12.94$278,210.0034,297View SEC Filing  
1/16/2018Jason HaddockCFOSell7,500$13.73$102,975.0036,368View SEC Filing  
12/19/2017Ron SquarerCEOSell819,671$10.86$8,901,627.06View SEC Filing  
12/18/2017Andrew R. RobbinsCOOSell282,874$10.72$3,032,409.28View SEC Filing  
9/29/2017Kyle LefkoffDirectorSell38,865$12.31$478,428.1551,585View SEC Filing  
3/28/2017Charles M BaumDirectorSell25,000$9.27$231,750.0030,000View SEC Filing  
9/28/2016Redmile Group, LlcMajor ShareholderSell2,492,578$6.36$15,852,796.08View SEC Filing  
9/15/2016Redmile Group, LlcMajor ShareholderBuy400,000$3.51$1,404,000.00View SEC Filing  
1/20/2016Redmile Group, LlcMajor ShareholderBuy300,000$3.19$957,000.00View SEC Filing  
1/12/2016Redmile Group, LlcMajor ShareholderBuy75,000$3.60$270,000.00View SEC Filing  
1/11/2016Redmile Group, LlcMajor ShareholderBuy925,000$3.67$3,394,750.00View SEC Filing  
10/1/2015Redmile Group, LlcMajor ShareholderBuy782,592$4.58$3,584,271.36View SEC Filing  
8/25/2015Redmile Group, LlcMajor ShareholderBuy790,000$5.38$4,250,200.00View SEC Filing  
8/10/2015Redmile Group, LlcMajor ShareholderBuy1,048,993$5.80$6,084,159.40View SEC Filing  
3/3/2015Kyle LefkoffDirectorSell70,000$8.00$560,000.00View SEC Filing  
3/2/2015Andrews R RobbinsSVPSell21,576$8.25$178,002.00View SEC Filing  
3/2/2015Ron SquarerCEOSell40,000$8.25$330,000.00View SEC Filing  
9/16/2013Liam RatcliffeDirectorSell1,673,172$6.08$10,172,885.76View SEC Filing  
9/6/2013Liam RatcliffeDirectorSell577,286$5.79$3,342,485.94View SEC Filing  
8/2/2013John R MooreVPSell75,384$7.02$529,195.68View SEC Filing  
7/23/2013John R MooreVPSell5,000$6.50$32,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Array Biopharma (NASDAQ ARRY) News Headlines

Source:
DateHeadline
Head to Head Analysis: InflaRx (IFRX) vs. Array BioPharma (ARRY)Head to Head Analysis: InflaRx (IFRX) vs. Array BioPharma (ARRY)
www.americanbankingnews.com - May 18 at 5:32 AM
Lunsen Gil J. Van Sells 21,500 Shares of Array BioPharma (ARRY) StockLunsen Gil J. Van Sells 21,500 Shares of Array BioPharma (ARRY) Stock
www.americanbankingnews.com - May 17 at 4:28 PM
Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual MeetingArray BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual Meeting
www.prnewswire.com - May 16 at 5:33 PM
Array BioPharma To Present At Bank Of America Conference; Webcast At 11:40 AMArray BioPharma To Present At Bank Of America Conference; Webcast At 11:40 AM
www.nasdaq.com - May 16 at 4:11 PM
Array BioPharma (ARRY) Upgraded by BidaskClub to "Hold"Array BioPharma (ARRY) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - May 15 at 1:21 PM
Array BioPharma (ARRY) Stock Rating Lowered by Zacks Investment ResearchArray BioPharma (ARRY) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 14 at 5:24 PM
FY2018 EPS Estimates for Array BioPharma Lifted by SunTrust Banks (ARRY)FY2018 EPS Estimates for Array BioPharma Lifted by SunTrust Banks (ARRY)
www.americanbankingnews.com - May 14 at 3:50 AM
FY2018 Earnings Estimate for Array BioPharma (ARRY) Issued By Piper JaffrayFY2018 Earnings Estimate for Array BioPharma (ARRY) Issued By Piper Jaffray
www.americanbankingnews.com - May 14 at 3:50 AM
Jefferies Group Comments on Array BioPharmas FY2018 Earnings (ARRY)Jefferies Group Comments on Array BioPharma's FY2018 Earnings (ARRY)
www.americanbankingnews.com - May 14 at 3:50 AM
Array BioPharma (ARRY) in Focus: Stock Moves 5.5% HigherArray BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher
finance.yahoo.com - May 11 at 11:08 AM
Will Array Biopharma Break Its Downtrend?Will Array Biopharma Break Its Downtrend?
finance.yahoo.com - May 11 at 11:08 AM
Array BioPharma slips 3% premarket after Roches unsuccessful late-state CRC studyArray BioPharma slips 3% premarket after Roche's unsuccessful late-state CRC study
seekingalpha.com - May 10 at 10:07 AM
Edited Transcript of ARRY earnings conference call or presentation 9-May-18 1:00pm GMTEdited Transcript of ARRY earnings conference call or presentation 9-May-18 1:00pm GMT
finance.yahoo.com - May 10 at 10:07 AM
Array BioPharma (ARRY) PT Set at $24.00 by Cantor FitzgeraldArray BioPharma (ARRY) PT Set at $24.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 10 at 9:08 AM
Array BioPharma (ARRY) Announces  Earnings Results, Beats Expectations By $0.11 EPSArray BioPharma (ARRY) Announces Earnings Results, Beats Expectations By $0.11 EPS
www.americanbankingnews.com - May 9 at 5:26 PM
Array BioPharmas (ARRY) CEO Ron Squarer on Q3 2018 Results - Earnings Call TranscriptArray BioPharma's (ARRY) CEO Ron Squarer on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 4:10 PM
Array Biopharma To Present At The Bank Of America Merrill Lynch 2018 Health Care ConferenceArray Biopharma To Present At The Bank Of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 9 at 4:10 PM
Array BioPharma Inc (NASDAQ:ARRY): Should The Recent Earnings Drop Worry You?Array BioPharma Inc (NASDAQ:ARRY): Should The Recent Earnings Drop Worry You?
finance.yahoo.com - May 9 at 4:10 PM
Array BioPharma beats by $0.11, beats on revenueArray BioPharma beats by $0.11, beats on revenue
seekingalpha.com - May 9 at 9:56 AM
Array BioPharma: Fiscal 3Q Earnings SnapshotArray BioPharma: Fiscal 3Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:56 AM
 Analysts Anticipate Array BioPharma (ARRY) Will Announce Quarterly Sales of $32.07 Million Analysts Anticipate Array BioPharma (ARRY) Will Announce Quarterly Sales of $32.07 Million
www.americanbankingnews.com - May 8 at 4:14 AM
Array BioPharma (ARRY) Given Average Recommendation of "Buy" by BrokeragesArray BioPharma (ARRY) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 7 at 9:05 AM
Reader Inquiry: Is Recent Weakness In Array BioPharma Warranted?Reader Inquiry: Is Recent Weakness In Array BioPharma Warranted?
seekingalpha.com - May 6 at 9:58 AM
 Analysts Anticipate Array BioPharma (ARRY) Will Post Earnings of -$0.22 Per Share Analysts Anticipate Array BioPharma (ARRY) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - May 6 at 5:49 AM
Array BioPharma (ARRY) Upgraded by ValuEngine to Strong-BuyArray BioPharma (ARRY) Upgraded by ValuEngine to Strong-Buy
www.americanbankingnews.com - May 4 at 12:21 AM
Array BioPharma (ARRY) Lifted to Buy at Zacks Investment ResearchArray BioPharma (ARRY) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - May 4 at 12:01 AM
Array BioPharma (ARRY) Scheduled to Post Quarterly Earnings on TuesdayArray BioPharma (ARRY) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 2:08 AM
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2018 On May 9, 2018Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2018 On May 9, 2018
finance.yahoo.com - April 30 at 4:07 PM
Array BioPharma (ARRY) Stock Rating Lowered by BidaskClubArray BioPharma (ARRY) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 24 at 11:02 AM
$32.07 Million in Sales Expected for Array Biopharma Inc (ARRY) This Quarter$32.07 Million in Sales Expected for Array Biopharma Inc (ARRY) This Quarter
www.americanbankingnews.com - April 21 at 4:52 AM
Array Biopharma Inc (ARRY) Expected to Announce Earnings of -$0.22 Per ShareArray Biopharma Inc (ARRY) Expected to Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - April 19 at 5:39 AM
Array Biopharma Inc (ARRY) Director Lunsen Gil J. Van Sells 21,500 SharesArray Biopharma Inc (ARRY) Director Lunsen Gil J. Van Sells 21,500 Shares
www.americanbankingnews.com - April 18 at 7:28 PM
Array Biopharma (ARRY) Downgraded by BidaskClub to "Strong Sell"Array Biopharma (ARRY) Downgraded by BidaskClub to "Strong Sell"
www.americanbankingnews.com - April 18 at 6:54 PM
Array Biopharma (ARRY) Given Buy Rating at Cantor FitzgeraldArray Biopharma (ARRY) Given Buy Rating at Cantor Fitzgerald
www.americanbankingnews.com - April 17 at 5:25 PM
See what the IHS Markit Score report has to say about Array Biopharma Inc.See what the IHS Markit Score report has to say about Array Biopharma Inc.
finance.yahoo.com - April 16 at 9:57 AM
Array Biopharma Inc (ARRY) Given Consensus Rating of "Buy" by BrokeragesArray Biopharma Inc (ARRY) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 12 at 8:49 AM
Stifel Nicolaus Reaffirms "Buy" Rating for Array Biopharma (ARRY)Stifel Nicolaus Reaffirms "Buy" Rating for Array Biopharma (ARRY)
www.americanbankingnews.com - April 11 at 3:24 PM
Array Biopharma (ARRY) Given a $13.00 Price Target by Cantor Fitzgerald AnalystsArray Biopharma (ARRY) Given a $13.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - April 11 at 12:43 AM
Array Biopharma (ARRY) Earns "Buy" Rating from Piper JaffrayArray Biopharma (ARRY) Earns "Buy" Rating from Piper Jaffray
www.americanbankingnews.com - April 10 at 10:31 PM
Array Biopharma Sees Unusually High Options Volume (ARRY)Array Biopharma Sees Unusually High Options Volume (ARRY)
www.americanbankingnews.com - April 6 at 8:03 AM
 Brokerages Expect Array Biopharma Inc (ARRY) Will Announce Quarterly Sales of $32.07 Million Brokerages Expect Array Biopharma Inc (ARRY) Will Announce Quarterly Sales of $32.07 Million
www.americanbankingnews.com - April 4 at 4:37 AM
Array Biopharma Inc (ARRY) Insider Victor Sandor Sells 8,689 SharesArray Biopharma Inc (ARRY) Insider Victor Sandor Sells 8,689 Shares
www.americanbankingnews.com - April 3 at 10:46 PM
ValuEngine Upgrades Array Biopharma (ARRY) to "Buy"ValuEngine Upgrades Array Biopharma (ARRY) to "Buy"
www.americanbankingnews.com - April 3 at 7:34 PM
Is There An Opportunity With Array BioPharma Inc’s (NASDAQ:ARRY) 32% Undervaluation?Is There An Opportunity With Array BioPharma Inc’s (NASDAQ:ARRY) 32% Undervaluation?
finance.yahoo.com - April 3 at 10:18 AM
Array Biopharmas (ARRY) "Buy" Rating Reiterated at Stifel NicolausArray Biopharma's (ARRY) "Buy" Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - April 2 at 3:42 PM
Cantor Fitzgerald Analysts Give Array Biopharma (ARRY) a $15.00 Price TargetCantor Fitzgerald Analysts Give Array Biopharma (ARRY) a $15.00 Price Target
www.americanbankingnews.com - March 30 at 10:36 PM
Array Biopharma (ARRY) Upgraded to Hold at BidaskClubArray Biopharma (ARRY) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - March 29 at 11:17 AM
Leerink Swann Upgrades Array Biopharma (ARRY) to OutperformLeerink Swann Upgrades Array Biopharma (ARRY) to Outperform
www.americanbankingnews.com - March 27 at 10:01 AM
Today’s Research Reports on Trending Tickers: Geron Corporation and Array BioPharma Inc.Today’s Research Reports on Trending Tickers: Geron Corporation and Array BioPharma Inc.
finance.yahoo.com - March 26 at 10:50 AM
Array Biopharma (ARRY) Rating Lowered to Sell at BidaskClubArray Biopharma (ARRY) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 23 at 11:20 PM

SEC Filings

Array Biopharma (NASDAQ:ARRY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Array Biopharma (NASDAQ:ARRY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Array Biopharma (NASDAQ ARRY) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.